Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial

Atherosclerosis

Volumn 251, Issue , 2016, Pages 367-372

  Tsujita, Kenichi ^a   Yamanaga, Kenshi ^a   Komura, Naohiro ^a   Sakamoto, Kenji ^a   Sugiyama, Seigo ^b   Sumida, Hitoshi ^c   Shimomura, Hideki ^d   Yamashita, Takuro ^e   Oka, Hideki ^f   Nakao, Koichi ^g   Nakamura, Sunao ^h   Ishihara, Masaharu ⁱ   Matsui, Kunihiko ^j   Sakaino, Naritsugu ^k   Nakamura, Natsuki ^l   Yamamoto, Nobuyasu ^m   Koide, Shunichi ⁿ   Matsumura, Toshiyuki ^o   Fujimoto, Kazuteru ^p   Tsunoda, Ryusuke ^q   Morikami, Yasuhiro ^r   Matsuyama, Koushi ^e   Oshima, Shuichi ^c   Kaikita, Koichi ^a   Hokimoto, Seiji ^a   Ogawa, Hisao ^a,s   more..

^a KUMAMOTO UNIVERSITY   (Japan)

^b Jinnouchi Hospital   (Japan)

^c Kumamoto Central Hospital   (Japan)

^d Fukuoka Tokushukai Hospital   (Japan)

^e Omuta Tenryo Hospital   (Japan)

^f Hlth Ins Hitoyoshi Gen Hospital   (Japan)

^g SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^h NEW TOKYO HOSPITAL   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

^k Department of Cardiovascular Internal Medicine Amakusa Medical Center   (Japan)

^l Shinbeppu Hospital   (Japan)

^m Nobeoka Prefectural Hospital   (Japan)

ⁿ Kumamoto Social Insurance General Hospital   (Japan)

^o NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^q JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^r KUMAMOTO CITY HOSPITAL   (Japan)

^s NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

more..

Author keywords

Ezetimibe; Intravascular ultrasound; Lipoprotein; Plaque; Statin

Indexed keywords

ATORVASTATIN; ATORVASTATIN PLUS EZETIMIBE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROTIC PLAQUE; BLOOD; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; INTERVENTIONAL ULTRASONOGRAPHY; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ATORVASTATIN CALCIUM; BIOMARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 85027944782     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.05.025     Document Type: Article

References (16)

1. [1] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 344 (1994), 1383–1389.
2. [2] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N. Engl. J. Med. 339 (1998), 1349–1357.
3. [3] Cannon, C.P., Braunwald, E., McCabe, C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 (2004), 1495–1504.
4. [4] Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Jama 291 (2004), 1071–1080.
5. [5] Nissen, S.E., Nicholls, S.J., Sipahi, I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 295 (2006), 1556–1565.
6. [6] Nicholls, S.J., Hsu, A., Wolski, K., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J. Am. Coll. Cardiol. 55 (2010), 2399–2407.
7. [7] Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372 (2015), 2387–2397.
8. [8] Tsujita, K., Sugiyama, S., Sumida, H., et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J. Am. Coll. Cardiol. 66 (2015), 495–507.
9. [9] Tsujita, K., Sugiyama, S., Sumida, H., et al. Plaque REgression with cholesterol absorption inhibitor or synthesis inhibitor evaluated by intravascular ultrasound (PRECISE-IVUS Trial): study protocol for a randomized controlled trial. J. Cardiol. 66 (2015), 353–358.
10. [10] Mintz, G.S., Garcia-Garcia, H.M., Nicholls, S.J., et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention 6 (2011), 1123–1130 1129.
11. [11] Davignon, J., Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109, 2004 III39–43.
12. [12] Baigent, C., Keech, A., Kearney, P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
13. [13] Puri, R., Nissen, S.E., Ballantyne, C.M., et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur. heart J. 34 (2013), 1818–1825.
14. [14] von Birgelen, C., Hartmann, M., Mintz, G.S., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 (2004), 1579–1585.
15. [15] Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 63 (2014), 2889–2934.
16. [16] Teramoto, T., Kashiwagi, A., Mabuchi, H., et al. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan atherosclerosis society guideline for diagnosis and treatment of hyperlipidemia in japanese adults: a study of the japan lipid assessment program (J-LAP). Curr. Ther. Res. Clin. Exp. 66 (2005), 80–95.